
                                SEQUENCE LISTING

<110> Belmares, Michael P.
      Garman, J. David
      Lu, Peter S.
      Salter, Michael W.
      Tymianski, Michael
      Arbor Vita Corporation
      NoNO, Inc.

<120> AGENTS AND METHODS FOR TREATMENT OF PAIN
  

<130> 026373-001010PC

<140> 
<141> 

<150> US 61/094,026
<151> 2008-09-03

<160> 19

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> Synthetic peptide Tat-NR2B9c

<400> 1
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Lys Leu Ser Ser Ile
 1               5                  10                  15      
Glu Ser Asp Val
            20  


<210> 2
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic 1990: a Tat peptide

<400> 2
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
 1               5                  10      


<210> 3
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic 1991: peptide 2B9c

<400> 3
Lys Leu Ser Ser Ile Glu Ser Asp Val
 1               5                  


<210> 4
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic 1992: peptide Tat-NR2B9c-AA

<400> 4
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Lys Leu Ser Ser Ile
 1               5                  10                  15      
Glu Ala Asp Ala
            20  


<210> 5
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic 1993: peptide F-Tat-NR2B9c

<400> 5
Phe Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Lys Leu Ser Ser Ile
 1               5                  10                  15      
Glu Ser Asp Val
            20  


<210> 6
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic 1994: peptide Tat-NR2B9c K to A

<400> 6
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala Leu Ser Ser Ile
 1               5                  10                  15      
Glu Ser Asp Val
            20  


<210> 7
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic 1995: peptide F-Tat-NR2B9c K to A

<400> 7
Phe Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala Leu Ser Ser Ile
 1               5                  10                  15      
Glu Ser Asp Val
            20  


<210> 8
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic 1987: D-isomer of Tat-NR2B9c

<400> 8
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Lys Leu Ser Ser Ile
 1               5                  10                  15      
Glu Ser Asp Val
            20  


<210> 9
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic 1976: peptide Tat-NR2B9c

<220> 
<221> MOD_RES        
<222> 20
<223> Xaa = norvaline

<400> 9
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Lys Leu Ser Ser Ile
 1               5                  10                  15      
Glu Ser Asp Xaa
            20  


<210> 10
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic 1977: peptide Tat-NR2B9c

<220> 
<221> MOD_RES        
<222> 20
<223> Xaa = L-t-butyl-glycine
      

<400> 10
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Lys Leu Ser Ser Ile
 1               5                  10                  15      
Glu Ser Asp Xaa
            20  


<210> 11
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic linker peptide

<400> 11
Gly Ser Ser Ser Ser
 1               5  


<210> 12
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic linker peptide

<400> 12
Thr Gly Glu Lys Pro
 1               5  


<210> 13
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic linker peptide

<400> 13
Gly Gly Arg Arg Gly Gly Gly Ser
 1               5              


<210> 14
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic linker peptide

<400> 14
Leu Arg Gln Arg Asp Gly Glu Arg Pro
 1               5                  


<210> 15
<211> 86
<212> PRT
<213> Human immunodeficiency virus 1

<220> 
<223> representative tat protein

<400> 15
Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser
 1               5                  10                  15      
Gln Pro Lys Thr Ala Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe
            20                  25                  30          
His Cys Gln Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr Gly
        35                  40                  45              
Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala His Gln Asn Ser Gln Thr
    50                  55                  60                  
His Gln Ala Ser Leu Ser Lys Gln Pro Thr Ser Gln Pro Arg Gly Asp
65                  70                  75                  80  
Pro Thr Gly Pro Lys Glu
                85      


<210> 16
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic tat peptide

<400> 16
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg
 1               5                  10  


<210> 17
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic tat peptide

<400> 17
Tyr Gly Arg Lys Lys
 1               5  


<210> 18
<211> 19
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic antennapedia internalization peptide

<400> 18
Ser Gly Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp
 1               5                  10                  15      
Lys Lys Cys
            


<210> 19
<211> 26
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic analgesic drug; Ziconotide

<400> 19
Cys Lys Gly Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys
 1               5                  10                  15      
Thr Gly Ser Cys Arg Ser Gly Lys Cys Gly
            20                  25      




